An Advanced MRI Abdomen Protocol to Evaluate Pancreatic Ductal Adenocarcinoma in Surgically Resectable and Borderline Resectable Disease for Loco-Regional Heterogeneity and To Evaluate Treatment Response Status Post Surgery and MRI-GRT
This is a prospective study evaluating imaging biomarkers in patients with either one of the following profiles: (1) resectable disease who are treated with surgical management (2) borderline resectable pancreatic adenocarcinoma who are treated with MR Guided Radiotherapy with restaging to surgically resectable disease (3) borderline resectable pancreatic adenocarcinoma who are treated with MR Guided Radiotherapy with continued treatment with non-surgical therapy including IRE or chemotherapy alone.
This is a prospective study evaluating for imaging biomarkers in patients with either one of the following profiles: (1) resectable disease who are treated with surgical management (2) borderline resectable pancreatic adenocarcinoma who are treated with MR Guided Radiotherapy with restaging to surgically resectable disease.
Histologically confirmed diagnosis of pancreatic adenocarcinoma.
Borderline Resectable Pancreatic Cancer (A. GDA encasement to the hepatic artery allowing: 1. Short segment encasement 2. Abutment without extension to the common hepatic artery. B. Tumor abutment of the SMA or CA (> ECOG Performance Score 0 or 1.
Patients must not have had major surgery, monoclonal antibody therapy, or experimental therapy within the 21 days prior to treatment.
Women of childbearing potential must have a negative serum or urine pregnancy test.
Patients must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other study requirements
Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
Any condition which, in the investigator’s opinion, makes the patient unsuitable for trial participation.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub